SAN DIEGO, Sept. 13 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the Stifel Nicolaus Annual Healthcare Conference on Friday, September 17, 2010 at 8:35 a.m. EDT (5:35 a.m. PDT). The conference is being held at the Four Seasons in Boston. Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will provide an overview of Anadys and its clinical development programs.
Dr. Worland will also present a Company overview at the UBS Global Life Sciences Conference on Wednesday, September 22, 2010 at 12:30 p.m. EDT (9:30 a.m. PDT). The conference is being held at the Grand Hyatt New York.
Each presentation will be webcast at the time of presentation and can be accessed on the Investor Relations page of the Company's website at www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to each presentation to download or install any necessary software. A replay of the presentation at the Stifel Nicolaus Annual Healthcare Conference will be available approximately one hour after the live webcast concludes and will be available through October 1, 2010. A replay of the presentation at the UBS Global Life Sciences Conference will be available approximately one hour after the live webcast concludes and will be available through October 6, 2010.
Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C. The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines. The Company is developing ANA598, a direct-acting antiviral or DAA, for the treatment of hepatitis C. In an ongoing Phase II study, the Company has completed 12 weeks of dosing ANA598 added to current standard of care. The Company has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.
Safe Harbor Statement
Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel medicines for the treatment of hepatitis C. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-Q for the quarter ended June 30, 2010. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
|SOURCE Anadys Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved